Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
January 11, 2021
– European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 – Phase 3 EDELWEISS…
Read morepress release
January 7, 2021
Geneva, Switzerland and Boston, MA – January 7, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
Read morepress release
January 4, 2021
Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreJune 9, 2020
May 8, 2019
Event
January 31, 2021
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
– European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 – Phase 3 EDELWEISS…
Read moreMedia Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile